DMC Recommends Resuming Phase III Takeda, Millennium, Amgen MONET1 Trial
This article was originally published in PharmAsia News
Executive Summary
TOKYO - An independent data monitoring committee has recommended that Takeda/Amgen/Millennium's MONET1 Phase III trial resume enrollment of patients with non-squamous non-small cell lung cancer, following a three-month enrollment suspension, a Takeda spokesman said Feb. 12
You may also be interested in...
Millennium Poised To Deliver Late-Stage Pipeline: Q&A With Dr. Karen Ferrante
Since its acquisition by Takeda in 2008, Millennium has been advancing its candidates and expanding its pipeline through deals, M&A and the assumption of internal Takeda oncology products. Near-term, it is expecting EU approval of ADCETRIS, licensed from Seattle Genetics, in the second half of 2012.
Following Millennium Merger, Takeda's Hopes Dashed To Be Among Number Three In Japan
Takeda and Millennium's combined oncology unit has 13 molecules in clinical development, six of which are in Phase II or III, including potential first-in-class opportunities
Following Millennium Merger, Takeda's Hopes Dashed To Be Among Number Three In Japan
Takeda and Millennium's combined oncology unit has 13 molecules in clinical development, six of which are in Phase II or III, including potential first-in-class opportunities